Patent Listings. [[Organization A:Organization]] shall have the sole right to make all filings with Regulatory Authorities in the Territory with respect to [[Party:Organization]] Product Patents, [[Organization A:Organization]] Patents, and Joint Patents, including as required or allowed # in the United States, in the FDA’s Orange Book if in the future legislation employs the Orange Book for biologics, or its alternative, and # outside the United States, under the national implementations of [Article 10.1(a)(iii)] of Directive 2001/EC/83 or other international equivalents. [[Party:Organization]] shall # provide to [[Organization A:Organization]] all Information, including a correct and complete list of [[Party:Organization]] Patents covering any Licensed Product or otherwise necessary or reasonably useful to enable [[Organization A:Organization]] to make such filings with Regulatory Authorities in the Territory with respect to such Patents, and # cooperate with [[Organization A:Organization]]’s reasonable requests in connection therewith, including meeting any submission deadlines, in each case ((a) and (b)), to the extent required or permitted by Applicable Law.

Patent Listings. [[Party:Organization]] shall have the sole right to make all filings with Regulatory Authorities in the Territory with respect to [[Party:Organization]] Nanobody Patents and take all decisions in respect of the same, including as required or allowed # in the United States, in the FDA’s Orange Book if in the future legislation employs the Orange Book for biologics or its alternative, and # outside the United States, under the national implementations of [Article 10.1(a)(iii)] of Directive 2001/EC/83 or other international equivalents. [[Party:Organization]] shall in good faith consult with [[Organization A:Organization]] where listing of the [[Party:Organization]] Nanobody Patents for the Licensed Compound or Licensed Products are concerned.